Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)- CALGB 80802 (Alliance) Abou-Alfa, Ghassan K. , Niedzwieski, Donna , Knox, Jennifer J. ... - ASCO GI - J. Clin. Oncol. - 2016 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80802
NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)--interim review of toxicity Alberts, S. R. , Morlan, B. W. , Kim, G. P. , Pitot, H. C. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007 Abstract - Primary Endpoint - Preliminary Analysis - GI - NCCTG-N044J
Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance) Clarke, Jeffrey M. , Pang, Herbert , Starr, Mark D. , Hatch, Ace ... - ASCO GI - J. Clin. Oncol. - 2015 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80303
Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000 Dematteo, R. P. , Owzar, K. , Antonescu, C. R. , Maki, R. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z9000
Initial results of CALGB 80803: A randomized phase II trial of pet scan-directed combined modality therapy for esophageal cancer (Alliance) Goodman, Karyn A. , Niedzwiecki, Donna , Hall, Nathan ... - ASCO GI - J Clin Oncol - 2017 Abstract - Primary Endpoint - Preliminary Analysis - GI - CALGB-80803
Baseline quality of life (QOL) is a strong and performance status (PS)-independent prognostic factor for overall survival (OS) in patients with metastatic colorectal cancer (mCRC) Grothey, A. , Sargent, D. J. , Szydlo, W. , Zhao, X. , Campbell, M. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N9741
Associations of Physical Activity with Survival and Progression in Metastatic Colorectal Cancer: Results from CALGB 80405 (Alliance) Guercio, Brendan J. , Venook, Alan P. , Niedzwiecki, Donna ... - ASCO GI - J Clin Oncol - 2017 Abstract - Secondary Endpoint - Preliminary Analysis - GI - CALGB-80405
Phase II study of oxaliplatin, 5-FU and RT followed by gemcitabine in patients with unresectable pancreatic cancer. Haddock, M. , Kim, G. , Foster, N. , Bollinger, J. , Stella, P. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N0349
On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance) Hatch, Ace J. , Ou, Fang-Shu , Zemla, Tyler , Liu , Star, Mark D. ... - ASCO GI - J. Clin. Oncol - 2019 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405
Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147 Huang, J. , Sargent, D. J. , Mahoney, M. R. , Thibodeau, S. N. ... - ASCO GI - J Cin Oncol 29, No 4_suppl (February - 2011 Abstract - Primary Endpoint - Primary Analysis - GI - N0147 , NCCTG-N0147
A Pilot Case Control Study: Could a Gastric Cancer Risk Screening Tool Help Identify High Risk Patients for Endoscopic Screening in the US? In, Haejin , Langdon-Embry, Marisa , Gordon, Lauren ... - ASCO GI - J Clin Oncol - 2018 Abstract - Primary Endpoint - Primary Analysis - Disparities - Pilot
Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU) and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer Kim, G. P. , Haddock, M. G. , Foster, N. , Bollinger, J. , Stella, P. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Primary Endpoint - Long-Term-Followup Analysis - GI - NCCTG-N0349
Time-dependent patterns of treatment effect and failure as an explanation for the predictive role of deficient mismatch repair (dMMR) in colon cancer. Kim, G. , Marsoni, S. , Monges, G. , Allegra, C. , Thibodeau, S. N. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N994C
HapB3 and the deep intronic variant c.1129-5923 C>G of the dihydropyrimidine dehydrogenase gene (DPYD) as predictors of toxicity in Stage III colon cancer (CC) patients (pts) (NCCTG N0147) (Alliance) Lee, Adam M. , Shi, Qian , Alberts, Steven R. , Sargent, Daniel J. ... - ASCO GI - J. Clin. Oncol. - 2015 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - N0147
Phase II trial of oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin for metastatic colorectal cancer Mcwilliams, R. , Goetz, M. , Morlan, B. , Salim, M. , Rowland, K., Jr ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N0341
Combined-modality therapy of poor prognosis anal canal carcinoma: a phase II study of the Cancer and Leukemia Group B (CALGB) Meropol, N. J. , Niedzwiecki, D. , Shank, B. , Colacchio, T. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2005 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-9281
Use of the ratio of metastatic to examined lymph nodes to predict local recurrence in rectal cancer: Analysis of data from intergroup trial 0114. Meyers, M. O. , Hollis, D. R. , Mayer, R. J. , Goldberg, R. M. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2009 Abstract - Secondary Endpoint - Primary Analysis - GI - INT-0114
Primary and Secondary Endpoint Analysis of N08C9 (Alliance)- A Phase III Randomized Trial of Sulfasalazine versus Placebo in the Prevention of Acute Radiation Enteritis Miller, R. C. , Petereit, D. G. , Sloan, J. A. , Liu, H. ... - ASCO GI - J. Clin. Oncol. - 2015 Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - N08C9
Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB 80405 (Alliance) Ng, Kimmie , Venook, Alan P. , Sato, Kaori , Hollis, Bruce W. ... - ASCO GI - J. Clin. Oncol. - 2015 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80405
Overall and 12 week tumor response versus actual tumor measurements as predictors of overall survival (OS) in advanced colorectal cancer (ACRC): Findings from NCCTG N9741. Sargent, D. J. , Campbell, M. E. , Grothey, A. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N9741
Association of RAS mutations with race in metastatic colorectal cancer CALGB 80405 (Alliance) Sehdev, Amikar , Niedzwiecki, Donna , Venook, Alan P. ... - ASCO GI - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80405
Evaluation of recurrence rate,time-to-recurrence, and hepatic metastases in patients with colon cancers with defective DNA mismatch repair. Sinicrope, F. , Foster, N. R. , Sargent, D. J. , Thibodeau, S. N. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N994C
Immunoscore provides prognostic information in low (T1-3N1) and high risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance) Sinicrope, Frank A. , Shi, Qian , Hermitte, Fabienne ... - ASCO GI - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - N0147
Long-chain omega-3 fatty acid and fish intake after colon cancer diagnosis and disease-free, recurrence-free, and overall survival CALGB 89803 (Alliance) Van Blarigan, Erin L , Fuchs, Charles S. , Niedzwiecki, Donna ... - ASCO GI - J Clin Oncol - 2017 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
